{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:46:10Z","timestamp":1789267570766,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.modpat.2023.100164","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T12:50:03Z","timestamp":1679662203000},"page":"100164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-4055","authenticated-orcid":false,"given":"Yan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tozbikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V.","family":"Parwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1696","authenticated-orcid":false,"given":"Zaibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.modpat.2023.100164_bib1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2023.100164_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.modpat.2023.100164_bib3","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100164_bib4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.modpat.2023.100164_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","article-title":"HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles","volume":"35","author":"Zhang","year":"2022","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2023.100164_bib7","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.modpat.2023.100164_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2023.100164_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2021.08.016","article-title":"Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer","volume":"60","author":"Mutai","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.modpat.2023.100164_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236059","article-title":"Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers","volume":"13","author":"Jacot","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-021-01492-x","article-title":"Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry","volume":"23","author":"Gampenrieder","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.modpat.2023.100164_bib14","article-title":"In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100164_bib15","article-title":"Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer","volume":"14","author":"Alves","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-022-01519-x","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society","volume":"24","author":"Won","year":"2022","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2023.100164_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clbc.2022.02.008","article-title":"Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression","volume":"22","author":"Rosso","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12916-022-02284-6","article-title":"HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis","volume":"20","author":"Tan","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.modpat.2023.100164_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.21873\/cdp.10111","article-title":"Prognostic significance of low HER2 expression in patients with early hormone receptor positive breast cancer","volume":"2","author":"Douganiotis","year":"2022","journal-title":"Cancer Diagn Progn"},{"issue":"5","key":"10.1016\/j.modpat.2023.100164_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12282-022-01364-y","article-title":"Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer","volume":"29","author":"Chen","year":"2022","journal-title":"Breast Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2023.100164_bib22","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100164_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/ajcp\/aqy136","article-title":"Identification of HER2 immunohistochemistry-negative, FISH-amplified breast cancers and their response to anti-HER2 neoadjuvant chemotherapy","volume":"151","author":"Gibbons-Fideler","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"23","key":"10.1016\/j.modpat.2023.100164_bib24","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.modpat.2023.100164_bib25","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.modpat.2023.100164_bib26","first-page":"1145","article-title":"Trastuzumab deruxtecan in HER2-low breast cancer. Reply","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.modpat.2023.100164_bib27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.modpat.2023.100164_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100164_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-low breast cancers","volume":"157","author":"Zhang","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12885-023-10634-7","article-title":"Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression","volume":"23","author":"Shi","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.modpat.2023.100164_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152125","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer","volume":"64","author":"Qiao","year":"2023","journal-title":"Ann Diagn Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100164_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100087","article-title":"HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100164_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database","author":"Peiffer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.modpat.2023.100164_bib34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2021.39.15_suppl.1021","article-title":"Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2\/neu (4B5) assay","volume":"39","author":"Scott","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100164_bib58","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/cancers14102509","article-title":"Impact of HER2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer","volume":"14","author":"Domergue","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2023.100164_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.996434","article-title":"Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world","volume":"9","author":"Di Cosimo","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13073-022-01104-z","article-title":"Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas","volume":"14","author":"Berrino","year":"2022","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1186\/s12885-022-10163-9","article-title":"HELENA: HER2-low as a predictive factor of response to neoadjuvant chemotherapy in early breast cancer","volume":"22","author":"Cherifi","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.modpat.2023.100164_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"de Nonneville","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2023.100164_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.modpat.2023.100164_bib40","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1245\/s10434-022-12369-4","article-title":"Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis","volume":"29","author":"Shao","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.modpat.2023.100164_bib41","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1128\/MCB.24.19.8681-8690.2004","article-title":"Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2\/neu\/phosphatidylinositol 3-kinase\/Akt signaling pathway","volume":"24","author":"Guo","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100164_bib42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12 Suppl","key":"10.1016\/j.modpat.2023.100164_bib43","first-page":"4429s","article-title":"Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"Suppl 36","key":"10.1016\/j.modpat.2023.100164_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.1142","article-title":"Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth","author":"Yarden","year":"2001","journal-title":"J\u00a0Cell Biochem Suppl"},{"issue":"4","key":"10.1016\/j.modpat.2023.100164_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.onc.1203416","article-title":"Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer","volume":"19","author":"Newman","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.modpat.2023.100164_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncology"},{"issue":"3","key":"10.1016\/j.modpat.2023.100164_bib47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.prp.2015.11.016","article-title":"Interobserver reproducibility for HER2\/neu immunohistochemistry: a comparison of reproducibility for the HercepTest\u2122 and the 4B5 antibody clone","volume":"212","author":"Layfield","year":"2016","journal-title":"Pathol Res Pract"},{"issue":"7","key":"10.1016\/j.modpat.2023.100164_bib48","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/clinchem\/hvab047","article-title":"Quantification of human epidermal growth factor receptor 2 by immunopeptide enrichment and targeted mass spectrometry in formalin-fixed paraffin-embedded and frozen breast cancer tissues","volume":"67","author":"Kennedy","year":"2021","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.modpat.2023.100164_bib49","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"Moutafi","year":"2022","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.modpat.2023.100164_bib50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jmoldx.2022.04.002","article-title":"Discordance between immunohistochemistry and Erb-B2 receptor tyrosine kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer","volume":"24","author":"Xu","year":"2022","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib51","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1186\/s12885-018-5172-1","article-title":"A\u00a0novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study","volume":"18","author":"Hicks","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2023.100164_bib52","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2353\/ajpath.2010.090711","article-title":"Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome","volume":"176","author":"Harigopal","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100164_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1309\/AJCP3BZY4YAFNTRG","article-title":"Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay","volume":"134","author":"Huang","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2023.100164_bib54","article-title":"Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens","volume":"2010","author":"Larson","year":"2010","journal-title":"Patholog Res Int"},{"issue":"1","key":"10.1016\/j.modpat.2023.100164_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13058-015-0543-x","article-title":"Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival","volume":"17","author":"Yardley","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.modpat.2023.100164_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/modpathol.2016.176","article-title":"A\u00a0novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2","volume":"30","author":"Jensen","year":"2017","journal-title":"Mod Pathol"},{"issue":"17","key":"10.1016\/j.modpat.2023.100164_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174250","article-title":"Can HER2 1+ breast cancer be considered as HER2-low tumor? A comparison of clinicopathological features, quantitative HER2 mRNA levels, and prognosis among HER2-negative breast cancer","volume":"14","author":"Shu","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:24:00Z","timestamp":1760232240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0893395223000698"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100164","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100164"}}